Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of treosulfan-based conditioning before allogeneic HSCT in pediatric hematologic malignancies
2013-003604-39Phase 2Completed
- Sponsor
- medac GmbH
- Start
- Dec 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of treosulfan in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 1 more, sponsored by medac GmbH. Primary endpoint: Freedom from transplant-related mortality. Started Dec 2013; status: completed.
02
Drugs
treosulfan
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on 2013-003604-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003604-39.